StockData
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$1.94−0.05 (-2.27%)

Close on Nov 17, 2026Market cap $422.73MP/E –Yield –

CytomX Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

CytomX Therapeutics's pe ratio was 14.2× on Jan 30, 2026, against 5.0× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jan 30, 202614.2×+3.6
2025Dec 31, 202510.7×+4.6
2024Dec 31, 20246.1×–

More CytomX Therapeutics figures

See a number that looks wrong?